Personal sequencing platforms will enter the clinical diagnostic arena this year, a majority of voters on a recent GEN poll predict. While 56.4% of respondents anticipate that sequencing instrument companies will continue to develop more user-friendly and cheaper technology, focused on the benchtop and clinical markets, 35.9% do not believe success will be seen this year and 7.7% undecided.

Research, discovery, and development applications still comprise the largest sequencing markets, but the largest market opportunity by far is in personal genomics and clinical diagnostics. Those segments are expected to reach $541 million by 2015 from $15.5 million in 2010. Recent advancements in next-generation sequencing have resulted in the advent of so-called personal genome machines. However, companies aiming at the clinical space will need to gain regulatory approval for their use in clinical laboratory diagnostics.

Previous articleBiopharma Investment Grows During Q4 but VCs Fund Fewer Early Deals
Next articleAcademic Institutions Won Most of CIRM’s $1.3B in Awards over Past Five Years